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Unsafe abortionImproving the care of women who have undergone a spontaneous or induced abortion is an important step
in reducing abortion-related morbidity and mortality. Both the International Federation of Gynecology and
Obstetrics (FIGO) and the World Health Organization recommend the use of manual vacuum aspiration (MVA)
and misoprostol rather than sharp curettage to treat incomplete abortion. MVA was introduced into the public
healthcare service in Benin in 2006 and since 2008misoprostol has been available in 3 large maternity hospitals.
The present study opted to use an oral dose of 800 μg and not to limit to pregnancies of up to 12 weeks, but to
include women with second trimester abortions. After 5 years, results show that around three-quarters of the
women treated with misoprostol at 13–18 weeks of pregnancy required MVA to complete uterine evacuation
and approximately one-quarter had severe bleeding, conﬁrming that the indication of misoprostol for incom-
plete abortion should be limited to pregnancies of up to 12 weeks.
© 2014 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Maternal mortality has been an issue of great concern in Benin
for decades. The high maternal mortality ratio has remained virtually
unchanged, from 474 maternal deaths per 100 000 live births in 2001
to 397 in 2006. Accordingly, approximately 1500 women die each
year in the process of giving birth. It is estimated that 15% of those
deaths are related to induced, mostly unsafe, abortions [1].
In an effort to achieve the ﬁfth Millennium Development Goal,
in 2006 Benin implemented a policy for preventing unsafe abortion
and improving postabortion care. Initially, manual vacuum aspiration
(MVA) was introduced to replace sharp curettage, followed by the
adoption of misoprostol for the treatment of incomplete abortion.
There is already ample experience on the use of misoprostol for
the treatment of incomplete abortion, as reﬂected in publications in
scientiﬁc journals and in the recommendations of the World Health
Organization (WHO) and the International Federation of Gynecology
and Obstetrics (FIGO) [2,3]. Most of the literature, however, refers to
clinical trials in which the recommendations are strictly followed.
Few publications deal with experiences in which those recommenda-
tions are applied in low-resource countries such as Benin and in hospi-
tals in which the demand of women requesting postabortion care
is heavy. In addition, to the best of our knowledge there have been noHospital, 01BP107, Cotonou,
atin).
and Obstetrics. Published by Elsevier Ipublications on the success rate of misoprostol when larger doses are
used to treat an incomplete abortion beyond 12 weeks of pregnancy.
For that reason, 5 years after the introduction of misoprostol for the
treatment of incomplete abortion in 3 maternity teaching hospitals in
Benin using a protocol that differs from the one usually recommended,
it is time to review this experience and evaluate its results, particularly
in cases in which the drug was used after 12 weeks of pregnancy. The
present article presents an analysis of the data collected throughout
the entire period in which this pioneering experience was applied in
this region.
2. Materials and methods
A descriptive, prospective studywas conducted over a 5-year period
in 3 maternity hospitals in Cotonou, Benin: the Obstetrics and Gynecol-
ogy Clinic (CUGO) at the Hubert Koutoukou Maga National Teaching
Hospital; the Lagoon Mother and Child Hospital (HOMEL); and the
Ménontin Maternity Hospital.
The study population consisted of all women admitted to the 3
aforementioned hospitals between January 1, 2008, and December 31,
2012, with a diagnosis of incomplete abortion. Women were not in-
cluded in the study if they had had a complete abortion that did not
require active treatment or if they had severe complications requiring
immediate action—a situation in which there would be no time or
opportunity to collect data. They were also not included if gestational
age was more than 18 complete weeks or if the woman was unable
to provide information on gestational age and physical examination
showed a uterine size compatible with the late second trimester.reland Ltd. Open access under CC BY-NC-ND license.
Table 1
The percentage of incomplete abortions treated with misoprostol in the three
participating hospitals in Cotonou, Benin (2008–2012).
CUGO HOMEL Ménontin Total
Year No. % No. % No. % No. %
2008 14/116 12.1 12/156 7.7 10/112 8.9 36/384 9.4
2009 34/243 14.0 33/186 17.7 53/230 23.0 120/659 18.2
2010 49/143 34.3 45/153 29.4 26/143 18.2 120/439 27.3
2011 52/185 28.1 50/198 25.3 28/111 25.2 130/494 26.3
2012 53/214 24.8 52/192 27.1 26/127 20.5 131/533 24.6
Total 202/901 22.4 192/885 21.7 143/723 19.8 537/2509 21.4
Abbreviations: CUGO, Obstetrics and Gynecology Clinic at the Hubert Koutoukou Maga
National Teaching Hospital; HOMEL, Lagoon Mother and Child Hospital; Ménontin,
Ménontin Maternity Hospital.
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in obstetrics and gynecology or residents in training, received the
women consulting for incomplete abortion. The diagnosis of incomplete
abortion was based on a clinical examination and on an ultrasonogra-
phy scan carried out in the emergency department.Womenwere candi-
dates for misoprostol treatment if they were hemodynamically stable
and uterine contents at ultrasonography were less than 20 mm. They
were counseled on the option of medical treatment, and informed
about the other alternatives available, thus the women were given the
right to choose themethod they preferred. Counseling also emphasized
the need to return for a follow-up visit at which they would be offered
an effective contraceptive method. Together with the advantages, the
women were also informed of the possible adverse effects of medical
treatment, principally pain and bleeding but occasionally diarrhea,
hyperthermia, and chills.
Patients who opted for medical treatment received 800 μg of miso-
prostol (Cytotec R; Pﬁzer, NY, USA) in the form of four 200-μg tablets
placed under the tongue in the presence of the provider and kept in
place for a period of 30 minutes.
Follow-up appointments were made for 3 days later to verify prog-
ress and for 15 days later when ultrasonography was performed to
monitor uterine contents. If the uterus was empty or ultrasonography
showed minimal uterine contents, but the woman was asymptomatic,
the procedure was considered successful and no further treatment
was given. If the uterus was not empty and the woman was bleeding
or still cramping, the procedure was considered to have failed and
the woman underwent MVA unless she was stable and wanted to try
a second 800-μg dose of misoprostol. In the latter case she received a
second dose of misoprostol and an appointment was set for 10–15
days later. If the uterus was still not empty after this second follow-
up, the patient underwent MVA.
Once it was conﬁrmed that the uterus was empty, the women were
offered a contraceptive method of their choice; however, particular em-
phasiswas placed on the advantages of long-acting reversible contracep-
tives (LARCs) such as the copper T 380 intrauterine device (IUD) and the
Jadelle (Bayer Healthcare, Berlin, Germany) contraceptive implant.
The present paper describes the proportion of women with an in-
complete abortion who were treated with misoprostol in the 3 study
hospitals, and how this proportion changed over time. It also shows
the distribution of these women according to gestational age at the
time of the abortion, the adverse effects recorded, the results of the
ultrasonography scans at the follow-up control visit, and the success
rate deﬁned by the proportion of women who did not require MVA
to complete uterine evacuation. The associations between gestational
age and adverse effects and between gestational age and the success
rate were also analyzed, as well as which contraceptive methods
were adopted by the women during the follow-up period. Evaluation
of the adverse effects was based on the patient’s report and on the
clinical examination and ultrasound scan. The amount of bleeding
was evaluated according to the number of completely saturated
tampons used by each woman over a 24-hour period. Bleeding
was classiﬁed as heavy if the number of tampons used over 24 hours
was more than 4.
Data on the variables studied were collected prospectively using
specially designed clinical forms on which the data listed above had
to be recorded. The same forms were used in all 3 hospitals. The
data were checked manually to reduce possible data collection errors.
Excel 2007 (Microsoft, Redmond, USA) was used for data entry and
cleaning. The associations between gestational age and success rate
and between gestational age and the incidence of adverse effects were
evaluated using Epi Info (Centers for Disease Control and Prevention,
Atlanta, USA).
Everywomanwho elected to usemisoprostol for the treatment of an
incomplete abortion signed an informed consent form. The study was
evaluated and approved by the Internal Review Board of the School of
Health Sciences, University of Benin.3. Results
A total of 3139 women were admitted with an incomplete abortion
at the 3 participating hospitals over the 5-year period between January
2008 and December 2012. The number of patients seen at the CUGO
and Homel hospitals during the 5-year period was similar (n = 1150,
36.6% vs n = 1190, 35.3%, respectively), while only 880 cases (23.1%)
were attended at the Ménontin Maternity Hospital.
After examination, 630 of the 3139 women were diagnosed as
having had a complete abortion requiring no treatment. Of the re-
maining 2509 women, 48.1% (n = 1277) were treated with MVA
and 21.4% (n = 537) with misoprostol. The number of women treated
with misoprostol comprised less than 10% of all the women during
the ﬁrst year; however, this proportion increased to 10%–20% in the
different hospitals in the second year, stabilizing at around 25% in the
fourth year and decreasing slightly to just over 20% in the ﬁfth year of
observation (Table 1).
The gestational age of the 537women treatedwithmisoprostolwas:
10 weeks or less (64.1%; n = 344), 11–12 weeks (14.9%; n = 80),
13–14 weeks (13%; n = 70), and 15–18 weeks (8.0%; n = 43).
Misoprostol was administered either in a single 800-μg dose
or in two 800-μg doses for a total of 1600 μg. In 55.9% of the cases
(n = 300) only one 800-μg dose of misoprostol was required, whereas
in 44.1% (n = 237), the women received 2 doses or 1600 μg. Most of
the women who received misoprostol (94.4%) were treated as outpa-
tients, while 5.6% (n = 30) were admitted to hospital (data not shown
in tables).
Two-thirds of the women with pregnancies of up to 12 weeks used
only 1 dose ofmisoprostol (66%); however, this proportion decreased to
34% among those with pregnancies of 13–14 weeks and to 23% for
women with pregnancies of 15–18 weeks (data not shown in tables).
Gestational age was signiﬁcantly associated with the success rate,
deﬁned as the percentage of cases in which MVA was not required to
complete uterine evacuation. In women with pregnancies of up to
12 weeks, the success rate was 99.1%; however, this percentage
dropped to only 25.7% and 27.9% in the case ofwomenwith pregnancies
of 13–14 weeks and 15–18 weeks, respectively. At the ultrasound scan
performed on the 15th post-treatment day, residual uterine contents
were found in fewer than 5% of the women with pregnancies of up to
12 weeks. This proportion increased to 10% of women at 13–14 weeks
of pregnancy and to 14% of women with pregnancies of more than
14 weeks. However, all of these cases were clinically asymptomatic
and no interventions were performed (Table 2). In addition, 7.6% of
women with pregnancies of up to 12 weeks and around 3% of those
with pregnancies of 13–14 weeks failed to return for follow up and
are presumed to have had no complications. None of the women with
pregnancies of more than 14 weeks failed to return for their follow-up
visit. The differences in success rates according to gestational age were
statistically signiﬁcant (P b 0.001) (Table 2).
The most common adverse effects of misoprostol treatment were
pain, evaluated as severe, in 26.6% of patients (n = 143), chills in
Table 2
Presence of residual uterine contents at the follow-up ultrasound scan and subsequent management, according to gestational age at the time of abortion.a
Ultrasound report and management Weeks of pregnancy
b12 13–14 15–18 Total
No. % No. % No. % No. %
Clean 370 87.3 9 13 6 14 385 71.7
Residue present, but no intervention made 18 4.2 7 10 6 14 31 5.8
Residue removed with MVA 4 0.9 52 74 31 72 87 16.2
Failed to return for follow up 32 7.5 2 3 0 0 34 6.3
Total 424 100 70 100 43 100 537 100
Abbreviation: MVA, manual vacuum aspiration.
a Pearson χ2 = 318.1.α b 0.001.
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in 4.5% (n = 24).
Gestational age at the time of the abortion was also associated
with the incidence of adverse effects. The proportion of women with
severe pain, chills, hyperthermia, diarrhea, and heavy bleeding was
signiﬁcantly smaller (P b 0.001) in women with pregnancies of up to
12 weeks compared with those with pregnancies of 13–14 weeks or
more than 14 weeks (Table 3). There was little variation in the pro-
portion of women who complained of severe pain between women
with pregnancies of 13–14 weeks (93%) and those with pregnancies
of 15–18 weeks (100%). Heavy bleeding was observed only among
women with pregnancies of more than 12 weeks and was present
for approximately half of the woman with pregnancies of more than
14 weeks compared with only 7% among those with pregnancies of
13–14 weeks (Table 3).
Every woman treated withmisoprostol elected to use somemethod
of contraception, although the majority (70.8%) chose the combined
oral contraceptive pill. Just over one-quarter (25.7%) chose a LARC
method, with a preference for the Jadelle implant system (21.0%) rather
than the copper IUD (4.7%). Only 2.6% chose an injectable contraceptive
(depot-medroxyprogesterone acetate or Noristerat) and 0.9% (n = 5)
decided to use a natural or barrier method (data not shown in tables).
4. Discussion
Misoprostol was introduced in Benin in an attempt to reduce the
workload caused by the large number of women demanding postabor-
tion care at every maternity hospital in the country. Evaluation of this
experience shows that the method has been very well accepted by
both providers and clients. Nevertheless, although there was a rapid in-
crease in acceptance over the ﬁrst 3 years, reaching a level of approxi-
mately one-quarter of all patients, this level has remained unchanged
over the past 3 years of observation. It is important to remember that
not all women with an incomplete abortion are able to use misoprostol
and thosewith heavy bleeding, an infection, or hemodynamic instability
are not eligible to use this method. Therefore, the percentage of women
with an incomplete abortion who were able to choose misoprostol wasTable 3
Incidence of adverse effects followingmisoprostol treatment, according to gestational age
at abortion.
Adverse effects Weeks of pregnancy
≤12 13–14 15–18 Total P valuea
No. % No. % No. % No. %
Severe pain 35 8.3 65 93 43 100 143 26.6 b0.001
Chills 39 9.2 24 34 32 74 95 17.7 b0.001
Hyperthermia 16 3.8 20 29 22 51 58 10.8 b0.001
Diarrhea 18 4.2 13 19 25 58 56 10.4 b0.001
Heavy bleeding 0 0.0 5 7 19 44 24 4.5 b0.001
Total 424 70 43 537
a Yates χ2 test.affected by the severity of their complications at the time of their con-
sultation at one of the study hospitals.
A number of different doses and dose intervals have been used to
treat incomplete abortions [4–7]. By 2008, there was already a general
agreement that 600 μg of oral misoprostol should be the recommended
dose, with the effect expected to occur within a period of 7–10 days. On
the other hand, the single dose of 800 μg reported by Demetroulis et al.
[4] seemed anattractive option, as the effect appeared to be faster. In ad-
dition, one of the objectives of the present study was to verify whether
a higher dose would enable incomplete abortions to be treated in the
case of more advanced pregnancies. Accordingly, 800 μg was the dose
selected for the present study, since this dose has already been shown
to be very well tolerated and has been recommended byWHO for preg-
nancy termination up to the late second trimester of pregnancy [2].
When the present study was initiated, the authors were unaware of
the evidence showing that endometrial thickness is not a good indicator
of a need for further treatment [8] and the protocol required that a sec-
ond dose of misoprostol be given whenever ultrasound suggested the
presence of residual uterine contents. This explains the frequency with
which the dose of misoprostol was repeated; however, if the women
were completely asymptomatic and uterine contents were minimal,
the clinical criteria prevailed and the protocol was not always followed.
A more important difference between the present study and other
experiences that have been reported was that in the present case the
medical treatment of incomplete abortion with misoprostol was not
limited to the ﬁrst trimester of pregnancy. It was decided to apply this
method in pregnancies of up to 18 weeks as long as the women were
in a stable condition and were within easy access of the hospital should
any complication, particularly heavy bleeding, occur. The analysis of
the study results showed thatmisoprostol did notwork, asMVAwas re-
quired to complete uterine evacuation in almost 75% of cases in which
gestational age exceeded 12 weeks. In addition, all cases of heavy
bleeding and most of the cases of complaints of severe pain were in
women with pregnancies of more than 12 weeks of gestational age.
The success rate of 99.1% was similar to rates reported in other
studies [12–14]. It could be argued that there is an assumption that
there were no complications in any of the women who failed to return
for their follow-up visit and there is no way of showing that these
women did not, in fact, require surgical evacuation. The socioeconomic
status of these patients, however, makes it highly unlikely that they
would have gone to a private facility, knowing that they could receive
free care at any one of the hospitals involved in this study.
Less than 10% of the womenwith pregnancies of up to 12 weeks re-
ported adverse effects, which consisted principally of severe pain, chills,
fever, and diarrhea, and this ﬁnding is in agreement with other reports
[9–12]. The relatively high proportion (21%) of women with pregnan-
cies of more than 12 weeks who reported heavy bleeding is another
argument against the use of this treatment for incomplete abortion
in cases of more advanced pregnancy. In particular, if this treatment is
disseminated to places in which access to emergency care is difﬁcult,
the risk of heavy bleeding outweighs the beneﬁts of the treatment, in-
cluding its success rate.
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tals and for dissemination of this practice to the rest of the country
is to reduce the dose of misoprostol to 600 μg orally and to limit use to
patients with pregnancies not exceeding 12 weeks, in compliance
with international recommendations [13].
Despite these deviations from the usual procedures for the use of
misoprostol for this indication, analysis of this experience shows that
it was generically quite positive, although it also shows that greater
restrictions are required in limiting its indications, for gestational age
in particular. The most important ﬁnding of the present study is its
conﬁrmation that misoprostol should not be used to treat incomplete
abortion beyond 12 weeks of pregnancy.
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